Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 135 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Thrush Clear all

Conditions: Vaginitis, Bacterial Vaginosis, Yeast Vaginitis, Trichomonas Vaginitis
Interventions: Xpert® Xpress MVP test, Usual Care; Diagnostic Test
Lead sponsor: Sharon L Hillier; Other
Eligibility: 14 Years and older · Female only
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infections
Interventions: miconazole Lauriad, Clotrimazole; Drug
Lead sponsor: Valerio Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 21
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 17 more

Conditions: Covid19, Mucormycosis, Aspergillosis, Candida Infection
Interventions: Not listed
Lead sponsor: Montefiore Medical Center; Other
Eligibility: Not listed
Enrollment: 728 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Candidiasis, Chronic Mucocutaneous
Interventions: Amphotericin B; Drug
Lead sponsor: Matinas BioPharma Nanotechnologies, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Candidemia
Interventions: Not listed
Lead sponsor: T2 Biosystems; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: Birmingham, Alabama • San Francisco, California • Lexington, Kentucky + 2 more

Conditions: Aspergillosis, Candidiasis, Fungal Diseases, Mycoses
Interventions: Voriconazole; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Aspergillosis, Candidemia
Interventions: anidulafungin and voriconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy Enteritis
Interventions: Emapalumab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Infection, Candida, Non Albicans Species
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: Not listed
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diaper Rash
Interventions: 0.25 % Miconazole Nitrate Ointment; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: Up to 15 Months
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 5
States / cities: San Diego, California • Coral Gables, Florida • Miami, Florida + 2 more

Conditions: Candidiasis, Invasive, Candidemia
Interventions: SCY-078; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Jersey City, New Jersey

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Posaconazole, Fluconazole; Drug
Lead sponsor: Schering-Plough; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 17
States / cities: Tucson, Arizona • Jonesboro, Arkansas • Miami, Florida + 13 more

Conditions: Candidiasis, Oral, Thrush, Candidiasis
Interventions: Frio Oral Rinse; Drug
Lead sponsor: Biomedical Development Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Kansas City, Missouri • San Antonio, Texas

Conditions: Recurrent Vulvovaginal Candidiasis
Interventions: Fluconazole Tablet, IBREXAFUNGERP, Placebo oral tablet; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 25
States / cities: Phoenix, Arizona • San Diego, California • Lake Worth, Florida + 19 more

Conditions: Mycoses, Candidiasis, Invasive, Candidemia
Interventions: SCY-078, Fluconazole, Micafungin; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 24
States / cities: Birmingham, Alabama • Sacramento, California • Aurora, Colorado + 17 more

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Nystatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Birmingham, Alabama • Princeton, New Jersey

Conditions: Invasive Candidiasis
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 120 Days to 18 Years
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 19
States / cities: Little Rock, Arkansas • Orange, California • San Diego, California + 16 more

Conditions: Candidiasis, HIV Infections
Interventions: Methadone hydrochloride, Fluconazole; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1994
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Staphylococcal Infections, Yeast Infections, Candidiasis
Interventions: NDV-3 vaccine with alum IM, NDV-3 vaccine without alum IM, Placebo with alum IM, NDV-3 vaccine without alum ID; Biological
Lead sponsor: NovaDigm Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 164 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Candidiasis, Esophageal, HIV Infections
Interventions: Itraconazole, Fluconazole; Drug
Lead sponsor: Janssen Pharmaceuticals; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 18
States / cities: Tucson, Arizona • Los Angeles, California • San Diego, California + 14 more

Conditions: Pediatric Invasive Candidiasis
Interventions: Observational antifungal therapy; Drug
Lead sponsor: Duke University; Other
Eligibility: 120 Days to 18 Years
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 27
States / cities: Little Rock, Arkansas • Orange, California • Palo Alto, California + 24 more

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Nystatin, Fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Fresno, California • San Francisco, California • Baltimore, Maryland + 2 more

Conditions: Invasive Candidiasis, Esophageal Candidiasis, Oropharyngeal Candidiasis, Candidemia
Interventions: Micafungin (Mycamine); Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 4 Months to 23 Months
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 6
States / cities: Los Angeles, California • Orange, California • Louisville, Kentucky + 3 more

Conditions: Candidemia
Interventions: APX001; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Birmingham, Alabama • Davis, California • Sacramento, California + 5 more

Search by objective public record fields.

Point of Care Diagnosis of Vaginal Infections

Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients

Mucormycosis in COVID-19

CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis

Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)

Voriconazole to Prevent Systemic Fungal Infections in Children

A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects

Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis

Changing Patterns of Candida Infections in Urban Medical Centers

Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants

Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)

A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients

Novel Rinse to Treat in Oral Candidiasis in Cancer Patients

Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)

Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis

A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes

BIOPIC: Fungal Biomarkers for Diagnosis and Response to Therapy for Pediatric Candidemia

A Study to Assess the Effect of Concomitant Administration of Fluconazole on the Clinical Pharmacokinetics of Methadone

Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine

Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.

PEACE: Pediatric Antifungal Comparative Effectiveness

Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome

Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia